This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cox, D. A. Search for Related Content PubMed PubMed Citation Articles by Cox, D. A.

Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial

David A. Cox, MD, FACC^*,*, Gregg W. Stone, MD, FACC, Cindy L. Grines, MD FACC, Thomas Stuckey, MD, FACC, David J. Cohen, MD^||, James E. Tcheng, MD, FACC^¶, Eulogio Garcia, MD^#, Giulio Guagliumi, MD^**, Robert S. Iwaoka, MD, FACC^*, Martin Fahy, MSc, Mark Turco, MD, FACC, Alexandra J. Lansky, MD, FACC, John J. Griffin, MD, FACC, Roxana Mehran, MD, FACC CADILLAC Investigators

^* Mid Carolina Cardiology, Charlotte, North Carolina, USA
The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York, New York, USA
William Beaumont Hospital, Royal Oak, Michigan, USA
Moses Cone Memorial Hospital, Greensboro, North Carolina, USA
^|| Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
^¶ Duke Clinical Research Institute, Durham, North Carolina, USA
^# Hospital Gregorio Maranon, Madrid, Spain
^** Ospedali Riuniti di Bergamo, Bergamo, Italy
Doylestown Hospital, Doylestown, Pennsylvania, USA
Virginia Beach General Hospital, Virginia Beach, Virginia, USA

View larger version (28K): [in a new window]   Figure 1 Individual and composite adverse event rates at 30 days (upper graph) and 1 year (lower graph) in patients achieving optimal percutaneous transluminal coronary angioplasty (PTCA) results randomized to pre-procedural abciximab administration (white bars) versus no pre-procedural abciximab. The p values for all two-way comparisons in both graphs are non-significant. TVR = target vessel revascularization.

View larger version (39K): [in a new window]   Figure 2 Subgroup analysis for the one-year composite end point of death, disabling stroke, reinfarction, or ischemic target vessel revascularization, comparing patients achieving an optimal percutaneous transluminal coronary angioplasty (PTCA) result (n = 415) with all patients randomized to stent implantation (n = 1,036), displayed as hazard ratios (black boxes) with 95% confidence intervals (CI) (horizontal limit lines). OR = odds ratio.